Near the conclusion ESMO 2023, Mirati is also sponsoring New Horizons in the Treatment of KRAS-Driven NSCLC and GI Cancers, an industry satellite symposium with Luis Paz-Ares, M.D., Ph.D. of Hospital Universitario 12 de Octubre, Aparna Parikh, M.D. of Mass General Cancer Center, Harvard Medical School and Keith Kerr, MB ChB, FRCPath, FRCPE of NHS Grampian. The symposium will discuss advances in targeting KRAS-driven NSCLC with a focus on the current status and future development of KRASG12C inhibitors, review the current status of targeted therapies for GI cancers and discuss the importance of timely molecular testing. The symposium will be held on October 23 from 13:00-14:30 CEST in the Valencia Auditorium, Hall 10, IFEMA Madrid.